Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2006 Sep;67(5):283–304. doi: 10.1016/j.curtheres.2006.10.001

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial

Joachim F Wernicke 1,**, Joel Raskin 2, Amy Rosen 1, Yili L Pritchett 1,*, Deborah N D'Souza 1, Smriti Iyengar 1, Kelly Knopp 1, Trong K Le 1
PMCID: PMC3966007  PMID: 24678103

Abstract

Background:

Duloxetine hydrochloride, a selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor, is relatively balanced in its affinity for both 5-HT and NE reuptake inhibition and is the first US Food and Drug Administration-approved prescription drug for the management of diabetic peripheral neuropathic pain (DPNP).

Objectives:

The aim of this study was to determine whether management of DPNP with duloxetine interferes with the treatment of diabetes. It also examined the tolerability of long-term exposure to duloxetine with regard to the progression of diabetic complications, and assessed the impact of DPNP management with duloxetine versus routine care.

Methods:

This was a 52-week, multicenter, re-randomized, open-label extension of a parallel, double-blind, randomized, placebo-controlled, acute (12-week) study. Patients who completed the duloxetine or placebo acute treatment period were randomly reassigned in a 2:1 ratio to treatment with duloxetine 60 mg BID or routine care for an additional 52 weeks. The study included male and female outpatients aged ≥18 years with a diagnosis of DPNP caused by type 1 or type 2 diabetes. Over the course of the 52-week study, visits were scheduled on the following weeks (of the extension phase of the study): 1 (via phone only), 2, 4, 8, 12, 20, 28, 40, and 52. Tolerability was assessed by review and analyses of discontinuation rates, adverse events (AEs), laboratory data, vital signs, electrocardiographic results, concomitant medications, and diabetic complications. Treatment-emergent AEs (TEAEs) were defined as AEs that appeared during therapy (were not present at baseline) or were exacerbated during treatment. Data on AEs and concomitant medications were collected at every visit. Data on blood pressure, heart rate, and significant hypoglycemic events were collected at every visit starting from week 2. Fasting clinical chemistry and electrolyte group laboratory assessments were done at every visit, starting from week 4. Electrocardiographic data was collected at weeks 4 and 52, and glycosylated hemoglobin and lipid profile data were collected at weeks 20 and 52. Hematology and urinalysis laboratory assessments and diabetic complication assessments were done at week 52. All safety data was assessed in cases of early discontinuation. Treatment differences on quality of life (QOL) were compared using the Short Form-36 Health Status Survey (SF-36) and the EQ-5D instrument of the European Health-Related Quality of Life Measures. This was assessed at the last visit or at early discontinuation.

Results:

The open-label extension-phase study included 337 patients (duloxetine, n = 222; routine care, n = 115). For the duloxetine group, mean age was 60.2 years, 61.3% were male, and 78.4% were white. For the routine-care group, mean age was 58.9 years, 60.0% were male, and 74.8% were white. Mean weight was 95.3 kg for both groups. None of the TEAEs occurred significantly more often in the duloxetine-treated group than in the routine-care-treated group. No TEAEs were reported by >10% of patients in the duloxetine group. The TEAEs reported by >10% of patients in the routine-care group included dizziness (11.3%), somnolence (13.0%), headache (10.4%), and vomiting (10.4%). No significant differences were found between treatment groups in the occurrence of serious AEs or in the number of patients discontinuing because of AEs. Duloxetine was significantly better than routine care on the bodily pain subscale of the SF-36 (mean change: 1.5 vs −4.1; P= 0.021) and on the EQ-5D (mean change: −0.00 vs −0.09; P = 0.001).

Conclusions:

Over 52 weeks of follow-up, treatment of these diabetic patients with duloxetine for peripheral neuropathic pain was associated with outcomes similar to, or significantly better than, that of routine care on most measures of tolerability, diabetic complications, and QOL.

Key words: duloxetine, diabetic peripheral neuropathic pain, antidepressant, pain, serotonin, norepinephrine

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

References

  • 1.National Diabetes Information Clearinghouse . 2005. National Diabetes Statistics: Total prevalence of diabetes in the United States, all ages.http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm#7 Available at: Accessed March 28, 2005. [Google Scholar]
  • 2.Dyck P.J., Kratz K.M., Karnes J.L. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–824. doi: 10.1212/wnl.43.4.817. [published correction appears in Neurology. 1993;43:2345] [DOI] [PubMed] [Google Scholar]
  • 3.Ziegler D., Gries F.A., Spuler M., Lessmann F., Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group The epidemiology of diabetic neuropathy. J Diabetes Complications. 1992;6:49–57. doi: 10.1016/1056-8727(92)90049-q. [DOI] [PubMed] [Google Scholar]
  • 4.Pfeifer M.A., Ross D.R., Schrage J.P. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care. 1993;16:1103–1115. doi: 10.2337/diacare.16.8.1103. [DOI] [PubMed] [Google Scholar]
  • 5.Duby J.J., Campbell R.K., Setter S.M. Diabetic neuropathy: An intensive review. Am J Health Syst Pharm. 2004;61:160–176. doi: 10.1093/ajhp/61.2.160. [DOI] [PubMed] [Google Scholar]
  • 6.Sumner C.J., Sheth S., Griffin J.W. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–111. doi: 10.1212/wnl.60.1.108. [DOI] [PubMed] [Google Scholar]
  • 7.Max M.B., Culnane M., Schafer S.C. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589–596. doi: 10.1212/wnl.37.4.589. [DOI] [PubMed] [Google Scholar]
  • 8.Sindrup S.H., Ejlertsen B., Froland A. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol. 1989;37:151–153. doi: 10.1007/BF00558223. [DOI] [PubMed] [Google Scholar]
  • 9.Max M.B., Kishore-Kumar R., Schafer S.C. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain. 1991;45:3–9. doi: 10.1016/0304-3959(91)90157-S. discussion 1–2. [DOI] [PubMed] [Google Scholar]
  • 10.Backonja M., Beydoun A., Edwards K.R. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA. 1998;280:1831–1836. doi: 10.1001/jama.280.21.1831. [DOI] [PubMed] [Google Scholar]
  • 11.Harati Y., Gooch C., Swenson M. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000;14:65–70. doi: 10.1016/s1056-8727(00)00060-x. [DOI] [PubMed] [Google Scholar]
  • 12.Gimbel J.S., Richards P., Portenoy R.K. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003;60:927–934. doi: 10.1212/01.wnl.0000057720.36503.2c. [DOI] [PubMed] [Google Scholar]
  • 13.Rowbotham M.C., Goli V., Kunz N.R., Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain. 2004;110:697–706. doi: 10.1016/j.pain.2004.05.010. [published correction appears in Pain. 2005;113:248] [DOI] [PubMed] [Google Scholar]
  • 14.Rosenstock J., Tuchman M., LaMoreaux L., Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain. 2004;110:628–638. doi: 10.1016/j.pain.2004.05.001. [DOI] [PubMed] [Google Scholar]
  • 15.Goldstein D.J., Lu Y., Detke M.J. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118. doi: 10.1016/j.pain.2005.03.029. [DOI] [PubMed] [Google Scholar]
  • 16.Bolay H., Moskowitz M.A. Mechanisms of pain modulation in chronic syndromes. Neurology. 2002;59:S2–S7. doi: 10.1212/wnl.59.5_suppl_2.s2. [DOI] [PubMed] [Google Scholar]
  • 17.Basbaum A.I., Fields H.L. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309–338. doi: 10.1146/annurev.ne.07.030184.001521. [DOI] [PubMed] [Google Scholar]
  • 18.Clark F.M., Proudfit H.K. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: Anatomical evidence that A5 neurons modulate nociception. Brain Res. 1993;616:200–210. doi: 10.1016/0006-8993(93)90210-e. [DOI] [PubMed] [Google Scholar]
  • 19.Fields H.L., Heinricher M.M., Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219–245. doi: 10.1146/annurev.ne.14.030191.001251. [DOI] [PubMed] [Google Scholar]
  • 20.Fields H.L., Basbaum A.I. Central nervous system mechanisms of pain modulation. In: Wall P.D., Melzack R., editors. Textbook of Pain. Churchill Livingstone; New York, NY: 1999. pp. 309–329. [Google Scholar]
  • 21.FDA approves drug for neuropathic pain associated with diabetes. 2006. http://www.fda.gov/bbs/topics/news/2004/NEW01113.html [Google Scholar]
  • 22.Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol. 2001;25:871–880. doi: 10.1016/S0893-133X(01)00298-6. [DOI] [PubMed] [Google Scholar]
  • 23.Feldman E.L., Stevens M.J., Thomas P.K. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–1289. doi: 10.2337/diacare.17.11.1281. [DOI] [PubMed] [Google Scholar]
  • 24.Farrar J.T., Young J.P., Jr, LaMoreaux L. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158. doi: 10.1016/S0304-3959(01)00349-9. [DOI] [PubMed] [Google Scholar]
  • 25.Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. American Psychiatric Association; Washington, DC: 1994. [Google Scholar]
  • 26.World Medical Association Declaration of Helsinki . WMA; Ferney-Voltaire, France: 1989. Recommendations guiding medical doctors in biomedical research involving human subjects (WMA)http://wwwwma.net Available at: Accessed September 28, 2006. [Google Scholar]
  • 27.Ware J.E., Snow K.K., Kosinski M., Gandek B. The Health Institute, New England Medical Center; Boston, Mass: 1993. SF-36® Health Survey Manual and Interpretation Guide. [Google Scholar]
  • 28.Kind P. The EuroQoL Instrument: An index of health-related quality of life. In: Spilker B., editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven Publishers; Philadelphia, Pa: 1996. pp. 191–201. [Google Scholar]
  • 29.Ware J.E., Jr SF-36 health survey update. Spine. 2000;25:3130–3139. doi: 10.1097/00007632-200012150-00008. [DOI] [PubMed] [Google Scholar]
  • 30.Ware J.E., Kosinski M., Keller S.K. The Health Institute; Boston, Mass: 1994. SF-36® Physical and Mental Health Summary Scales: A User's Manual. [Google Scholar]
  • 31.Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748. [PubMed] [Google Scholar]
  • 32.Milliken G.A., Johnson D.E. Chapman and Hall; Boca Raton, Fla: 1993. Analysis of Messy Data, Volume I: Designed Experiments. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES